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Abstract
Abnormalities in levels of choline and its metabolites have been reported in the lesions of brains of X-linked
adrenoleukodystrophy (X-ALD) patients. We have examined the turnover of the major choline-containing phospholipid,
phosphatidylcholine (PtdCho), in fibroblasts from hemizygous X-ALD, heterozygous X-ALD, Zellweger syndrome (ZW),
and male and female control individuals to assess possible alterations in PtdCho metabolism mediated by activation of
protein kinase C (PKC). Hydrolysis of PtdCho by phospholipase D (PLD) and resynthesis of PtdCho from labeled choline
were stimulated 2- to 4-fold by PKC activation with the phorbol ester, 4L-12-O-tetradecanoylphorbol-13-acetate (L-TPA), in
all cells except those from heterozygous X-ALD individuals. No differences in quantity or intracellular distribution of PKC
activity, PKC isoforms by Western blot analysis, or of the PKC substrate, myristoylated alanine-rich C kinase substrate
(MARCKS), were apparent in any of the cells. Thus, altered PtdCho metabolism was not directly linked to either of these
inherited defects that result in abnormal peroxisomal functions. Further, altered responsiveness of PLD in X-ALD
heterozygotes was independent of changes in PKC and MARCKS. z 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Peroxisomal disorders are a heterogeneous group
of at least 17 di¡erent diseases characterized by im-
pairment of one or more peroxisomal functions [1,2].
One class involves defective assembly and biogenesis
of peroxisomes resulting in multiple enzyme de¢cien-
cies; Zellweger syndrome (ZW) is a prominent exam-
ple. Other disorders, such as X-linked adrenoleuko-
dystrophy (X-ALD), appear to represent an enzyme
or transporter defect with loss of a single peroxiso-
mal function [3^6]. X-ALD is one of the most fre-
quent peroxisomal disorders a¡ecting 1 in 15 000^
20 000 males [7] and occurs with di¡ering clinical
phenotypes, even within the same family [8,9]. Gen-
erally patients with the childhood, cerebral form de-
velop neurological symptoms at 5^12 years with the
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disease progressing to a terminal state within a few
years [5].
Accumulation of very long chain fatty acids
(VLCFA; s 24C) is a primary biochemical abnor-
mality in X-ALD [9,10]. Elevated levels of VLCFA is
also a marker of ZW as the normal capacity of
peroxisomes to metabolize these fatty acids through
L-oxidation also is impaired. Early studies of X-ALD
indicated an inability to activate and transport
VLCFA into peroxisomes for subsequent L-oxida-
tion [11,12].
More recently, the gene for X-ALD has been iden-
ti¢ed by positional cloning and the ALD locus
has been mapped to Xq28 [13^16]. This gene en-
codes an integral membrane protein (ALDP) of 745
amino acids [17]. Monoclonal antibodies to ALDP
cross-react with a 75 kDa protein in intact peroxi-
somes of normal ¢broblasts but no interaction is
detected in ¢broblasts from X-ALD patients
[18,19]. ALDP belongs to the ATP-binding cassette
(ABC) transporter protein family [9,20,21] that ap-
parently forms homo- or hetero-dimers with another
ALD-related protein (ALDRP) within the peroxiso-
mal membrane to produce functional transporters
[22]. Absence of ALDP in X-ALD can result from
nonsense mutations, frame shifts, deletions or inser-
tions [23^26]. This genetic variability, along with as
yet unde¢ned modi¢er genes, are predicted to ac-
count for the extensive phenotypic variability of X-
ALD even within the same kindred. A gene similar
to that for human X-ALD has been identi¢ed in
mice [27]. Mice with defective ALDP have impaired
peroxisomal L-oxidation of VLCFA but not patho-
logical abnormalities of the human disease, suggest-
ing that accumulation of VLCFA alone may not be
su⁄cient to cause defective myelination in the nerv-
ous system [28]. Despite appreciable new evidence
relating to the properties of the gene product and
its signi¢cant homology to the peroxisomal mem-
brane protein, PMP-70, clear and direct correlations
between genotype and phenotype remain to be deter-
mined.
Neurophysiological abnormalities associated with
X-ALD have been examined using multi-slice proton
magnetic resonance spectroscopy imaging and other
MRI techniques [29^31]. Elevation of choline con-
taining compounds has been shown in the brains of
X-ALD patients with actively demyelinating lesions
but not in those with stable lesions [31]. Reported
correlations with elevation of choline metabolites
suggested to us that changes in major choline-con-
taining phospholipids, phosphatidylcholine (PtdCho)
and sphingomyelin, that account for more than half
of the mass of membrane phospholipid structures
(including myelin membranes of the nervous system)
should be considered. While myelin membrane struc-
tures are relatively stable, turnover of membrane
phospholipids in the central nervous system does oc-
cur [32]. Hydrolysis of PtdCho, for example, by
phospholipase D (PLD) or phospholipase C results
in production of choline and phosphocholine, respec-
tively [33]. Accordingly, we reasoned that alterations
of PtdCho turnover in cells of X-ALD patients might
contribute to abnormal patterns of choline metabo-
lites and ultimately to progression of the disease at
the cellular level.
Our previous studies have shown that turnover of
PtdCho in neural cells can involve activation of PLD
mediated by speci¢c members of the large family of
protein kinase C (PKC) isoforms [34^37]. Recently,
we have shown that in human neuroblastoma cells,
not only is PKC-K required for phorbol ester stim-
ulation of PLD activity and PtdCho hydrolysis (as
demonstrated in numerous cell systems by others
also [38,39], but a prominent PKC substrate (myris-
toylated alanine-rich C kinase; MARCKS) found in
the nervous system also is essential for PtdCho deg-
radation by PLD and release of free choline and the
lipid second messenger, phosphatidic acid [40,41].
Only one study of PKC activities in cells of patients
with peroxisomal disorders has been reported [42]
and this was con¢ned to an evaluation of kinase
activity and endogenous substrate phosphorylation
in cells from ZW patients.
Accordingly, we now have evaluated turnover of
the major choline containing phospholipid in mem-
branes in ¢broblasts obtained from patients with X-
ALD and ZW syndrome. E¡ects of activation of
PKC on both PLD activities and resynthesis of
PtdCho have been determined and possible changes
in the predominant isoforms of PKC and its major
substrate, MARCKS, have been assessed in these
cells. Surprisingly, changes in PLD and PtdCho turn-
over were observed only in cells from heterozygous
X-ALD individuals and not in hemizygous X-ALD
or ZW cells. In none of these cases were signi¢cant
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di¡erences in PKC activity and distribution or the
presence of MARCKS observed.
2. Materials and methods
2.1. Materials
[methyl-3H]Choline chloride (81.0 Ci/mmol), [9,10-
3H (N)]myristic acid (14:0; 11.2 Ci/mmol), [Q-32P]-
ATP (1.0 mCi/mmol), [1-14C]oleic acid (18:1n-9;
56.0 mCi/mmol), [1-14C]eicosapentaenoic acid (20:
5n-3; 52.2 mCi/mmol), and 1-O-[alkyl-1P,2-3H]-sn-
glyceryl-3-phosphorylcholine (58.3 Ci/mmol) were
purchased from Dupont-New England. Minimum es-
sential medium (MEM) was purchased in premixed
powdered form from Gibco. Fetal bovine serum
(FBS) was from Flow Laboratories. Enhanced chem-
iluminescence detection, Hyper¢lm MP and PKC en-
zyme assay kits were from Amersham Canada. Anti-
bodies and peptides for all PKC isoforms were from
Santa Cruz. Phenylmethylsulfonyl£uoride, leupeptin,
pepstatin A, dimethyl sulfoxide, 4K- and 4L-12-O-
tetradecanoylphorbol-13-acetate (TPA), digitonin
and unlabeled choline chloride were from Sigma
Chemical Co. Glycerol, Tween-20, and TEMED
were from BDH and silica Gel HL-60 TLC plates
were from Analtech Inc. Silica Gel G TLC plates
were from Fisher Scienti¢c. Equipment and reagents
for sodium dodecyl sulfate^polyacrylamide gel elec-
trophoresis (SDS-PAGE) and Western blotting were
from Bio-Rad Canada. Triton X-100 (Surfact-Amps)
and micro-bicinchoninic protein assay kits were from
Pierce Chromatographic Specialties. Phosphatidylbu-
tanol standard was obtained from Avanti Polar
Lipids. All other chemicals were reagent grade and
obtained from various sources.
2.2. Cell culture
Cells were grown to con£uence for 7 days in
60 mm dishes at 37‡C in 5% CO2/95% air and
100% relative humidity in 5 ml MEM containing
10% FBS [43]. Spent medium was removed and fresh
medium was added 24^48 h before beginning experi-
ments. Control ¢broblasts were obtained from fore-
arm or foreskin biopsies of normal individuals.
Fibroblasts from patients with X-ALD or ZW or
from ALD carriers were obtained from the Human
Genetic Mutant Cell Repository or from the cell
bank at our laboratory (Atlantic Research Center).
Identity of type of disorder was based on clinical
history and biochemical analyses (VLCFA accumu-
lation for X-ALD and ZW and defective plasmalo-
gen biosynthesis for ZW only). Analysis, conducted
by the local cytogenetics laboratory (IWK Grace
Health Centre) to provide gender identi¢cation for
each culture, con¢rmed appropriate identi¢cation of
hemizygous and heterozygous X-ALD and other
cells.
2.3. Choline labeling studies
For 2 h pulse experiments, medium was removed
from cultured cells and replaced with 2 ml medium
containing 5 WCi [3H]choline and K- or L-TPA. After
2 h, cells were washed and harvested and lipids were
extracted [34]. Components of the aqueous phase
were analyzed by TLC using Silica G plates and a
solvent system of ethanol/2% ammonia (v/v; 1:2)
[44]. TLC of the lipid extract used chloroform/etha-
nol/water/triethylamine (4:5:1:4) [45]. Regions sepa-
rated were quantitated using a Bioscan 200 Imaging
Scanner.
For 30 min prelabeling studies, cells were incu-
bated with fresh medium without FBS and contain-
ing [3H]choline (2.5 WCi). After 30 min, medium was
removed and cells were washed twice with phos-
phate-bu¡ered saline at 37‡C. Fresh medium con-
taining 200 nM K- or L-TPA was added and cells
were incubated for various times. Medium was re-
moved and saved for counting and cells were har-
vested as above.
To assess stimulation by unsaturated fatty acids,
unlabeled 18:1n-9 was suspended in 5% sterile bo-
vine serum albumin [34,46]. Cells were pulsed with
5 WCi [3H]choline and 200 WM 18:1n-9 for 1 h and
harvested as above.
2.4. Phospholipase D activity
In choline release assays, cells were labeled with
[3H]choline for 48 h and medium was removed. Cells
were washed twice with PBS at 37‡C and incubated
in the presence of K- or L-TPA for various times in
2 ml fresh medium supplemented with 1 mM unla-
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beled choline. Medium was removed for scintillation
counting and TLC analyses. Cells were harvested as
above.
In transphosphatidylation assays, precursors (14:0,
18:1n-9, 20:5n-3 and alkyl-sn-glyceryl-3-phosphoryl-
choline) for labeling of phospholipids were sus-
pended in albumin as above and added to dishes of
cells for incubation for 18, 24, or 48 h [36,47]. Fol-
lowing prelabeling of cells, medium was changed and
after a further 1 h of equilibration, 1% 1-butanol and
K- or L-TPA were added. After various times, me-
dium was removed, cells were harvested and lipids
were extracted. Aliquots of lipid extract were ana-
lyzed for phosphatidylbutanol formation using Silica
HL 60 plates activated for 1 h at 80‡C and a solvent
system consisting of the organic phase of ethyl ace-
tate/isooctane/acetic acid/water (65:10:15:50) [48].
Phosphatidylbutanol standard was used and sepa-
rated regions were quantitated using a Bioscan 200
Imaging Scanner.
2.5. Protein analyses
Protein content of harvested cells was determined
using the Lowry method [49] and bovine serum al-
bumin as standard. Protein assays were done on
samples prior to Western blot analysis and autora-
diography.
2.6. PKC activity assays
Cells were treated for 15 min with 200 nM K-TPA
(controls) or L-TPA, medium was removed and cells
were fractionated as described previously [37,50].
PKC activity was measured using the
Amersham PKC assay that detects transfer of 32P
from [Q-32P]ATP to a synthetic PKC peptide sub-
strate.
2.7. SDS-PAGE and Western blot analysis of PKC
isoforms
Cells were treated for 15 min with 200 nM K-TPA
or L-TPA and medium was removed. Cytosolic and
particulate fractions were obtained [50] and sepa-
rated by SDS-PAGE (Bio-Rad mini-Protein II Sys-
tem) on a 10% polyacrylamide gel at 150 V [51].
Proteins were transferred to 0.45 Wm nitrocellulose
membrane for 90 min at 100 V and skim-milk
blocked membranes were incubated with primary
antibody. After washing six times, goat anti-rabbit
IgG conjugated to horseradish peroxidase was ap-
plied as secondary antibody for all PKC isoforms
except PKC-L, which used goat anti-mouse IgG con-
jugated to horseradish peroxidase. Membranes were
incubated with secondary antibody for 1 h and
washed six times for 8 min each. Immunoreactive
bands were detected using a chemiluminescent West-
ern blotting kit (Amersham) according to manufac-
turer’s instructions.
2.8. Analysis of MARCKS
Cells were labeled for 18 h with [3H]14:0 and me-
dium was removed and replaced with medium con-
taining 200 nM K-TPA or L-TPA. After 10 min,
medium was removed and heat stable protein frac-
tions of cytosol and detergent-extracted membranes
were obtained [50]. Sonicated samples were boiled
for 90 s prior to separation on SDS-PAGE as above.
[3H]Myristic acid labeled proteins were visualized by
£uorography.
3. Results
3.1. Choline labeling studies
Several methods for evaluating PtdCho turnover
were used to test whether PtdCho metabolism was
altered in ¢broblasts with peroxisomal mutations.
The phorbol ester, L-TPA, observed to stimulate
turnover of PtdCho in many cell lines [34,36,37],
was used to enhance PtdCho synthesis and/or degra-
dation in both control and mutant cell lines. The
inactive form of the phorbol ester, K-TPA, was
used as control in these and subsequent experiments.
In initial experiments, labeled choline was added at
the same time as phorbol ester to measure a combi-
nation of time-dependent uptake of choline and me-
tabolism to intermediates and the major product,
PtdCho.
Optimal concentration of L-TPA required for stim-
ulation of PtdCho synthesis, shown in numerous ex-
periments with other cell lines to be in a 50^200 nM
range [34,37,40,41,52], was determined for the ¢bro-
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blast cell lines. After a 2 h incubation, greatest stim-
ulation of choline incorporation into PtdCho oc-
curred at 200 nM L-TPA for control and X-ALD
¢broblasts and at 100 nM for ZW cells. Heterozyg-
ous X-ALD cells did not show increased choline in-
corporation into PtdCho at any concentration of
TPA examined. TLC of the lipid extract con¢rmed
that at 2 h, s 95% of radioactivity was in PtdCho
with 6 4% in sphingomyelin in all cell lines.
Fibroblasts were labeled for 30, 60 and 120 min to
determine the optimal incubation time for incorpo-
ration of labeled choline into PtdCho (Fig. 1). In
control and ZW cells, incorporation in response to
L-TPA treatment was greatest at 2 h with 3- and 2-
fold increases, respectively. Although incorporation
of choline into PtdCho increased with time in heter-
ozygous X-ALD cells, there was no enhanced incor-
poration in response to 200 nM L-TPA treatment at
any time examined. With all cells, there was an ap-
parent lag in label incorporation during the ¢rst 30^
60 min. In response to 200 nM L-TPA, control cells
initially showed an increase in labeled choline metab-
olites in the aqueous phase (data not shown), but by
2 h, label with L-TPA treatment was slightly less
than that for K-TPA controls. In ZW cells, there
was a 2-fold increase in choline in aqueous metabo-
lites in L-TPA treated cells. In heterozygous ALD
cells, there was no signi¢cantly change in aqueous
metabolites with L-TPA treatment at 1 or 2 h.
With K-TPA treatment, radioactivity was approxi-
mately 20% in choline and 80% in phosphocholine
in all cell lines; no appreciable CDP-choline or glyc-
erol-phosphorylcholine (6 2%) was detected. Rela-
tive radioactivity in phosphocholine decreased to
65% of total aqueous label after treatment with L-
TPA in control and ZW cell lines but the metabolite
pro¢le did not change in heterozygous X-ALD cells.
Lack of response to L-TPA treatment in hetero-
zygous X-ALD cells was further investigated in addi-
Fig. 2. E¡ect of L-TPA on choline incorporation into PtdCho
during a 2 h pulse in control and mutant ¢broblasts. Cells were
incubated for 2 h with 2.5 WCi [3H]choline and 200 nM K-TPA
(black bars) as controls or 200 nM L-TPA (open bars). Cells
were harvested and lipid extracts were analyzed as described in
the Section 2. Fibroblast cell lines indicated on the X-axis are:
A, B, control males; C, control female; D, ZW ¢broblasts; E,
F, G, three di¡erent hemizygous X-ALD ¢broblasts (male) ; H,
I, J, three di¡erent heterozygous X-ALD ¢broblasts (female).
Note that control A is a more rapidly growing and metabol-
ically active cell line than are the other controls. Values are
means þ S.E.M. for 6^14 independent samples.
Fig. 1. E¡ects of L-TPA on choline incorporation into PtdCho
over time in control and mutant ¢broblasts. Cells were incu-
bated for 30, 60, or 120 min with 2.5 WCi [3H]choline and
200 nM K-TPA (b) as controls or 200 nM L-TPA (a). Cells
were harvested and analyses of lipid extracts were performed as
described in Section 2. (A) Control ¢broblasts. (B) ZW ¢bro-
blasts. (C) Heterozygote X-ALD ¢broblasts. Note the di¡eren-
ces in y-axis scales. Values are means þ S.E.M. for 4^12 inde-
pendent samples.
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tional heterozygous ALD and hemizygous X-ALD
cell lines (Fig. 2). At 2 h with 200 nM L-TPA, hemi-
zygous X-linked cell lines (E, F, and G) responded
with a 2-fold increase in labeled choline incorpora-
tion into PtdCho. In heterozygous cell lines (H, I and
J), there was no response to L-TPA treatment. Addi-
tional male and female ¢broblast control cell lines
had a 2-fold increase in choline incorporation into
PtdCho with 200 nM L-TPA treatment.
18:1n-9 stimulates PtdCho synthesis in many cell
lines [34,37,53,54]. To determine whether the lack of
L-TPA response in heterozygous X-ALD cells was
speci¢c to phorbol ester, we also examined e¡ects
of 18:1n-9. In control, ZW, hemizygous X-ALD
and heterozygous X-ALD cells, 18:1n-9 stimulated
choline incorporation into PtdCho nearly 1.5-fold
(Fig. 3). This demonstrated that the CDP-choline
pathway of PdtCho synthesis can be stimulated in
all cell lines and that lack of responsiveness to L-
TPA in the heterozygous X-ALD cell lines is not
due to lack of capacity for enhanced PtdCho syn-
thesis.
Fig. 3. E¡ects of oleic acid and L-TPA on choline incorpora-
tion into PtdCho of control and mutant ¢broblasts. Cells were
incubated for 1 h with 2.5 WCi [3H]choline and bovine serum
albumin as controls (open bars), with 200 WM oleic acid
(18:1(n-9); slashed bars) complexed to bovine serum albumin
or with 200 nM L-TPA (cross-hatched bars). Cells were har-
vested and lipid extracts were analyzed as described in Section
2. BSA, bovine serum albumin; A, control ¢broblasts; B, ZW
¢broblasts; C, hemizygous X-ALD ¢broblasts; D, heterozygous
X-ALD ¢broblasts. Values are means þ S.E.M. for 4 independ-
ent samples.
Fig. 4. E¡ects of L-TPA on choline incorporation into PtdCho after a 30 min prelabeling in control and mutant ¢broblasts. Cells
were preincubated for 30 min with 2.5 WCi [3H]choline and media were removed. Cells were washed twice and incubated for another
15, 45, or 90 min with 200 nM K-TPA as controls (b) or with 200 nM L-TPA (a). Cells were harvested and lipid extracts were ana-
lyzed as described in Section 2. (A) Control ¢broblasts. (B) ZW ¢broblasts. (C) Hemizygous X-ALD ¢broblasts. (D) Heterozygous X-
ALD ¢broblasts. Note the di¡erences in y-axis scales. Values are means þ S.E.M. for 4^6 independent samples.
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3.2. Choline pulse-chase studies
Stimulation of choline incorporation into PtdCho
may be due to combinations of increased activity of
the biosynthetic pathway and an increase in trans-
port of labeled choline into the cells. To distinguish
the e¡ects of L-TPA treatment on transport (uptake
of exogenous choline from the extracellular medium)
from e¡ects of the phorbol ester on PtdCho biosyn-
thesis (incorporation of intracellular choline into
phospholipid), cells were prelabeled cells with choline
for 30 min, the label-containing medium was re-
moved and cells were stimulated with L-TPA. In
the absence of label in the media during subsequent
15, 45, or 90 min incubation, control ¢broblasts and
hemizygous X-ALD cells showed a 2-fold stimula-
tion of incorporation of labeled choline into PtdCho
(Fig. 4). In ZW cells (Fig. 4B), no stimulation of
label incorporation was observed in contrast to
pulse-labeling results. The heterozygous X-ALD cells
also did not respond to L-TPA treatment, consistent
with previous pulse-labeling observations. The e¡ect
of L-TPA on the distribution of label among total
aqueous metabolites was examined (data not shown).
A greater decrease in labeled choline metabolites,
mainly phosphocholine, was observed in response
to L-TPA treatment in control ¢broblasts, but not
in heterozygous and hemizygous X-ALD cell lines.
3.3. PLD activity
Metabolism of phospholipids in cells not in a rapid
growth phase involves combinations of synthesis and
hydrolysis by several phospholipases. PLD has been
reported to increase hydrolysis of PtdCho in many
cell systems in response to phorbol ester treatment,
through activation of PKC [38,39]. PLD hydrolysis
can be measured by labeling cells with choline for
48 h, removing the label, and stimulating cells with
L-TPA. As shown in Fig. 5, PLD activity released
labeled choline (s 95% of the label) to the medium
when 1 mM unlabeled choline was present in the
chase medium to restrict recycling of label. In re-
sponse to L-TPA treatment, control ¢broblasts
showed a 2-fold stimulation of choline release where-
as none of the mutant cell lines responded. As this
Fig. 5. E¡ects of L-TPA on choline release to the media following a 48 h prelabeling of control and mutant ¢broblasts. Cells were
preincubated for 48 h with 10 WCi [3H]choline and media were removed. Cells were washed twice before the addition of 1 mM un-
labeled choline and 200 nM K-TPA as controls (b) or 200 nM L-TPA (a) for another 15, 45, and 90 min. Cells were harvested and
analyses of label in the medium was performed as described in Section 2. (A) Control ¢broblasts. (B) ZW ¢broblasts. (C) Hemizygous
X-ALD ¢broblasts. (D) Heterozygous X-ALD ¢broblasts. Values are means þ S.E.M. for 6 independent samples.
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was unexpected based on previous results showing a
L-TPA response in X-ALD hemizygotes and ZW
cells, a transphosphatidylation assay of PLD activity
also was used.
A useful catalytic property of PLD is its relative
speci¢city for replacing the headgroup of phospho-
lipids with an alcohol rather than water when a pri-
mary alcohol is present at relatively low concentra-
tions (0.1^3%) [55,56]. Phosphatidylalcohols formed
are not metabolized rapidly and their accumulation
can be quantitated as a measure of PLD activity.
Control ¢broblasts were treated with 4 labeled
precursors of phospholipids ([3H]14:0, [14C]18:1n-9,
[1-14C]20:5n-3 or [3H]lysoalkylphosphatidylcholine)
for 18, 24 or 48 h. All PtdCho precursors were in-
corporated extensively into phospholipids. 14:0 was
most speci¢c (s 95%) for labeling of PtdCho at 18 h.
In the transphosphatidylation assay [47] to examine
PLD activity in mutant cell lines (Fig. 6), control
¢broblasts responded to L-TPA treatment with ap-
proximately a 4-fold increase in phosphatidylbutanol
formation. In ZW and hemizygous X-ALD cells
stimulated with L-TPA, PLD activity increased
2- to 3-fold. Consistent with previous observations
of PdtCho synthesis, the heterozygous X-ALD cell
lines did not respond signi¢cantly to L-TPA treat-
ment to increase formation of phosphatidylbutanol.
Similar results were obtained with all labeled precur-
sors.
3.4. PKC activity, isoforms and substrate analyses
To investigate whether lack of responsiveness to L-
TPA in heterozygous X-ALD cells was due to altered
PKC activity, PKC was assayed in vitro (Fig. 7). In
all cell lines under basal conditions (i.e., K-TPA con-
trols), PKC activity was predominantly in the cyto-
sol. In response to L-TPA treatment, there was a
translocation of activity from the cytosol to the par-
ticulate fraction in all cell lines. Further, after 15 min
L-TPA treatment downregulation of total PKC ac-
tivity was observed in control ¢broblasts and all mu-
Fig. 7. E¡ects of L-TPA on PKC activity in control and mutant
¢broblasts. Cells were treated for 15 min with 200 nM K-TPA
as controls or with 200 nM L-TPA. Cytosol (open and upward-
slashed bars) and membrane (particulate) fractions were ob-
tained as described in Section 2. Fractions were assayed for
PKC activity using [Q-32]ATP and a synthetic peptide substrate
in the presence of calcium and lipid activators. Cells examined
are shown on the x-axis : A, control ¢broblasts; B, ZW ¢bro-
blasts; C, hemizygous X-ALD ¢broblasts; D, heterozygous X-
ALD ¢broblasts. Values are means þ S.E.M. for 6 independent
samples.
Fig. 6. E¡ects of L-TPA on PLD measured as phosphatidylbu-
tanol formation in control and mutant ¢broblasts. Cells were
labeled for 18 h with 2 WCi [3H]myristic acid and media were
removed. Cells were washed once before the addition of fresh
media for 1 h. Cells were incubated for another 1 h with 1% 1-
butanol and 200 nM K-TPA (black bars) as controls or with
1% butanol and 200 nM L-TPA (open bars). Cells were har-
vested and lipid extracts were analyzed as described in Section
2. Di¡erent ¢broblast cell lines indicated on the x-axis are: A,
control ¢broblasts; B, ZW ¢broblasts; C, D, E, hemizygous X-
ALD ¢broblasts; F, G, heterozygous X-ALD ¢broblasts. Val-
ues are means þ S.E.M. for 6^8 independent samples. *Not sig-
ni¢cantly di¡erent; Ps 0.05 compared to K-TPA treatment.
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tant cell lines. PKC and lipid independent kinase
activities both increased in the particulate fractions
of all cells treated with L-TPA. PKC activities in K-
TPA treated cells were lower in mutant ¢broblasts
than in control cells, probably related to the overall
lower growth rate and metabolic activity of these
mutant cell lines.
Total PKC activity measurements do not di¡eren-
tiate among di¡erent isoforms of PKC. Western blot
analyses using isoform-speci¢c antibodies (Fig. 8)
showed that all cell lines contained PKC-K, -O, -W,
and -j. Analyses with antibodies for PKC-L, -Q, -N,
-R, and -a revealed that none of these isoforms were
present in any cell lines examined. PKC-K, -O, and -W
were predominantly in the cytosol under basal con-
ditions in all cells, but were translocated to the mem-
brane fraction with a concurrent depletion of cyto-
solic protein in response to treatment with L-TPA. In
all cell lines, PKC-j was found predominantly in the
cytosol with some detected in the membrane frac-
tion; PKC-j distribution did not change in response
to treatment with L-TPA.
MARCKS is a major myristoylated, membrane
PKC substrate implicated in the turnover of PtdCho.
[3H]Myristic acid was used to radiolabel the
MARCKS protein to allow for detection by SDS-
Fig. 9. Fluorography of MARCKS in control and mutant cell lines. Cells were labeled for 18 h with [3H]myristic acid. Medium was
removed and replaced with medium containing 200 nM K-TPA (3) for controls or 200 nM L-TPA (+) and incubated for 10 min. Cy-
tosol (C) and membrane (M) fractions were isolated using digitonin and Triton X-100 bu¡ers and heat treated for 10 min at 80‡C.
These samples were centrifuged and the supernatant was precipitated with acetone for 2 h at 320‡C. Pellets were resuspended in SDS
sample bu¡er and separated on 10% polyacrylamide gels prior to autoradiography. Designations for cell lines were as described for
Fig. 8. In addition total cell lysate from a human neuroblastoma cell line (SK-N-SH; see [52]) was included as a control.
Fig. 8. Western blot analysis of PKC isoforms in control and mutant cell lines. Cells were treated for 15 min with 200 nM K-TPA
(3) for controls or with 200 nM L-TPA (+). Medium was removed and cells were washed with phosphate-bu¡ered saline. Cytosol (C)
and membrane (M) fractions were isolated using digitonin and Triton X-100 in bu¡ers and fractions were precipitated with acetone
overnight as described in Section 2. Samples were centrifuged and pellets were resuspended in SDS sample bu¡er and separated on
10% polyacrylamide gels. Gels were subjected to Western blot analysis using commercial antibodies for PKC isoforms. Cell lines ex-
amined were: FM1, control male ¢broblasts; ZW, Zellweger syndrome ¢broblasts; ALD HM1, hemizygous X-ALD ¢broblasts; ALD
HZ1, heterozygous X-ALD ¢broblasts.
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PAGE and £uorography (Fig. 9). MARCKS is a
heat stable protein and a 10 min incubation at
80‡C was used to denature heat labile proteins and
partially purify extracts; MARCKS was the only
myristoylated protein appearing in the 80 kDa region
of the gel [50,52,57], as shown in Fig. 9. The levels of
labeled MARCKS did not di¡er in the four cell lines
with approximately equal amounts found in the cy-
tosol and membrane fractions. Di¡erences between
samples from cells treated with L-TPA were not de-
tected, although MARCKS is known to be translo-
cated from the membrane to the cytosol after phos-
phorylation by PKC in some cells [57].
4. Discussion
Previous reports of elevated concentrations of
choline metabolites in brain of X-ALD patients [31]
suggested to us that PtdCho metabolism might be
altered in X-ALD patients. Accordingly, we initiated
this investigation of the regulation of the synthesis
and degradation of PtdCho through PKC-mediated
mechanisms. In other studies [38,39,58], it has been
shown that PLD is activated by treatment of cells
with L-TPA, presumably through the activation of
PKC, resulting in enhanced hydrolysis of membrane
phospholipids. Interactions of PKC with PLD ap-
pear to involve both phosphorylation and nonphos-
phorylation mechanisms [38,59] and to be dependent
on the isoforms of both PKC and PLD expressed in
speci¢c cell lines [39]. In our study, a sensitive and
direct transphosphatidylation assay was used as a
measure of PLD activity in control, ZW and hetero-
zygous and hemizygous X-ALD cell lines. As pre-
dicted, PLD activity was stimulated in control ¢bro-
blasts in response to L-TPA and also in ZW and
hemizygous X-ALD cells. Surprisingly, heterozygous
X-ALD cells did not respond signi¢cantly to L-TPA
with an increase in phosphatidylbutanol formation
from PLD hydrolysis of PtdCho.
Changes in PtdCho turnover can be initiated by
stimulation of either synthesis or degradation of the
phospholipid. When cells are not proliferating, levels
of membrane PtdCho appear to be tightly main-
tained so that overall mass does not change appreci-
ably. Accordingly, regulation of synthesis and deg-
radation should be coordinately balanced. The
apparent lag in stimulated synthesis for the ¢rst
15 min of incubation, measured as choline incorpo-
rated into PtdCho in control, ZW, and hemizygous
X-ALD cell lines, probably indicates that degrada-
tion of PtdCho occurs prior to increased synthesis.
We [36,40,41] and others [54] have interpreted this
delay in PtdCho synthesis in response to PKC acti-
vation as a re£ection of resynthesis, secondary to an
initial degradation of membrane PtdCho by PLD to
generate lipid second messengers. All ¢broblast cell
lines in this study have the capacity for enhanced
PtdCho synthesis based on stimulation by 18:1n-9;
however, this fatty acid does not stimulate PLD hy-
drolysis of PtdCho in cells treated in this manner
[36].
To determine whether lack of response of PtdCho
synthesis and degradation to L-TPA treatment in
heterozygous ALD ¢broblasts might be due to di¡er-
ences in quantity and distribution of PKC activity,
individual PKC isoform protein or a primary PKC
substrate, MARCKS, we assessed these parameters
in each type of ¢broblast cell line. In all cells, there
were no major di¡erences in PKC activity, measured
in vitro as peptide phosphorylation, between TPA-
nonresponsive heterozygous X-ALD cells and the
other responsive control, hemizygous X-ALD and
ZW cells. In all mutant and control cell lines, L-
TPA treatment resulted in translocation of PKC ac-
tivity from the cytosol to the membrane fraction ac-
companied by some loss of total activity consistent
with PKC down regulation [37,60^62]. Although
basal levels of PKC activity seemed slightly lower
in the cytosolic fraction of mutant cells compared
to controls, activity measurements in the membrane
compartment before and after L-TPA induced trans-
location did not di¡er among cell lines. Therefore,
di¡erences in total PKC catalytic activity seem an
unlikely explanation for the lack of L-TPA response
in heterozygous X-ALD cells.
In another study of ZW ¢broblasts [42], an in-
crease in basal PKC catalytic activity was observed
in ZW compared to control cells. Our study did not
indicate this di¡erence for ZW cells as both basal
and TPA-stimulated membrane PKC activities were
the same as for controls. These apparent discrepan-
cies between our results and those previously re-
ported for ZW cells may relate to di¡erences in the
protocol for evaluating PKC activity. We used a
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highly speci¢c peptide containing the PKC phos-
phorylation site of the epidermal growth factor re-
ceptor in our assays in contrast to the use of calf
thymus histone protein (type III-S), a more general
kinase substrate, in the previously published work
[42]. Further, in that report of altered phosphoryla-
tion of endogenous substrates in ZW cells, evidence
was not presented to indicate that PKC was the
kinase responsible for the di¡erence in phosphoryla-
tion patterns in intact ZW cells compared to con-
trols; e¡ects of activation of PKC by L-TPA on en-
dogenous substrate phosphorylation were not
examined in that study. Accordingly, the earlier
study [42] indicates possible di¡erences in kinase ac-
tivities in ZW cells compared to controls but evi-
dence has not been provided to substantiate altered
PKC activity.
From our observations, we conclude that di¡eren-
ces in total PKC activity cannot explain altered
PtdCho metabolism in heterozygous X-ALD cell
lines in response to L-TPA. Speci¢c examination of
the expression and translocation of individual PKC
isoforms in response to L-TPA treatment showed
that four isoforms, PKC-K, -O, -W, and -j, were
present in human ¢broblasts with no di¡erences ap-
parent in any of the mutant or heterozygous cell
lines. Consistent with previous observations with ¢-
broblasts [37,60,62,63], the conventional isoform,
PKC-K, and the novel isoforms, PKC-O and -W,
were found predominantly in the cytosol under basal
conditions and translocated to the membrane after L-
TPA treatment; PKC-j was found predominantly in
the membrane and its distribution was not altered by
L-TPA treatment. Accordingly, lack of L-TPA re-
sponse in heterozygous X-ALD cells cannot be due
to absence of a speci¢c protein kinase C isoform
among the eight isoforms tested. PKC-K was of par-
ticular interest because its involvement in PtdCho
turnover has been indicated in several cell lines
[33,39] and has been extensively investigated in our
laboratory in four cell lines of neural origin
[36,37,40]. Recently, our laboratory also reported
that transfection of PKC-K into a usually nonrespon-
sive human neuroblastoma cell line did not alone
restore capacity for L-TPA-enhanced turnover of
PtdCho; interestingly, transfection of unresponsive
cells with MARCKS not only restored response to
L-TPA but also resulted in increased expression of
endogenous PKC-K in neuroblastoma clones [40,41]
(Morash et al., 1997, unpublished). PKC-K and -L
have been implicated in the activation of PLD
in several studies [38,39,58] and our recent data sup-
port PLD as the initial site for activation in both
responsive cells and clones transfected with
MARCKS. As the other classical isoforms, PKC-L
and Q, were not expressed in any of the human ¢bro-
blast lines (controls or mutants) in the present study,
we thought that alterations in PKC-K might explain
lack of L-TPA responsiveness in heterozygous X-
ALD cell lines. Although not quantitated in detail,
there was indication in all three mutant cell types
that PKC-K might be translocated from the cytosol
to the membrane more completely than in control
¢broblasts. This, however, does not provide an ex-
planation for the lack of response to L-TPA in het-
erozygotes speci¢cally as these minor di¡erences in
PKC-K translocation were observed in all mutant cell
lines.
The unanticipated observation that heterozygous
X-ALD cell lines examined did not respond to L-
TPA treatment with either an increase in PLD activ-
ity or an increase in choline incorporation into
PtdCho was in distinct contrast to the response of
the hemizygous X-ALD cell lines. Apparently, lack
of response can not be attributed directly to the X-
ALD mutation itself. We assessed the possibility that
observed di¡erences might be related to gender, as
ALD is an X-linked disease so that carriers are fe-
male whereas a¡ected X-ALD patients are male (like
the donors of ZW and most control cells) ; however,
female control cells had similar levels of all parame-
ters examined as did male control cells. While we do
not have a satisfying explanation at this point for our
observations with heterozygotes, it is interesting to
speculate that they may relate to the process of X-
inactivation, where only one of two X-chromosomes
is expressed and only one of two alleles remains ac-
tive. Some X-linked genes are thought to escape X-
inactivation and a¡ect phenotypic expression of X-
linked disorders [64]. Heterozygous females can have
a much less severe form of the disease, with 70% of
carriers developing some symptoms [2,65]. Perhaps
X-inactivation alters some other gene product in£u-
encing the response of PLD and the resynthesis of
PtdCho to L-TPA. Another consideration is that the
di¡erential responses may relate to an unidenti¢ed
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autosomal modi¢er gene implicated in the character-
istic phenotypic heterogeneity of X-ALD [27].
Although this gene has not been isolated and char-
acterized, there has been speculation about its func-
tion and relationship to the primary gene defect. Pos-
sibly this autosomal modi¢er gene might be involved
at some level of modulation of PtdCho metabolism.
Identi¢cation of this proported gene should lead to
an understanding of its role in phenotypic expression
of X-ALD and a role for it in PtdCho metabolism
should be considered. Studies of other genetic disor-
ders have revealed changes in speci¢c cellular param-
eters in heterozygotes for gene defects that are not
re£ected in homozygous cells [66].
In conclusion, our study has revealed abnormal-
ities in PtdCho turnover involving stimulation of
PLD activity by L-TPA treatment of heterozygous
X-ALD cell lines only, compared to control, hemi-
zygous X-ALD and ZW cell lines. Mechanisms be-
hind this di¡erential response have not been deter-
mined but several possibilities have been eliminated.
Lack of PLD stimulation does not appear to involve
substantially altered expression or activity of PKC as
PKC translocation, activity and isoform expression
did not di¡er in the heterozygotes compared to the
other cell lines. Treatment with oleic acid con¢rmed
that PtdCho synthesis can be stimulated even in het-
erozygotes that do not respond to L-TPA treatment.
It is apparent that responsiveness of PLD in X-ALD
heterozygous carriers, but not in hemizygous X-
ALD, is altered independent of changes in PKC
and MARCKS, a primary mediator of PKC and
PLD interactions.
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